

Cyklus EHK: E21/24 - Endokrinologie 2

Stop termín: 2.2.2024

Nastavení: skupiny - M (princip měření), R (výrobce reagentů); Slovensko; minimální četnost skupin n = 5

RoM = robustní průměr

SD = směrodatná odchylka

CV = variační koeficient

N_{tot} = celkový počet výsledkůN_{out} = počet výsledků vyloučených před výpočtem

AV = vztažná hodnota

CVPG = konsenzus skupin účastníků

U_{AV} = rozšířená nejistota vztažné hodnoty (k = 2)D_{max} = přijatelný rozdíl

LL = dolní mez

UL = horní mez

N_{eva} = počet hodnocených výsledkůN_{suc} = počet úspěšných výsledkůS_{rel} = relativní úspěšnost

| Zkouška Vzorek Skupina | [jednotka] | RoM | SD | CV [%] | N _{tot} | N _{out} | Srovnatelnost | | | | | N _{eva} | N _{suc} | S _{rel} [%] |
|---|------------|------|------|--------|------------------|------------------|---------------|---|------------------|-----|------|------------------|------------------|----------------------|
| | | | | | | | AV | U _{AV} | D _{max} | LL | UL | | | |
| (393) C-peptid | [pmol/L] | | | | 10 | | | | | | | 7 | 7 | 100 |
| Vzorek A | | 460 | 86 | 19 | 10 | | | | | | | 7 | 7 | 100 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 516 | 23 | 4,5 | 5 | 0 | CVPG | 513 | 15 | 20% | 410 | 616 | 5 | |
| Ostatní | | | | | 5 | 0 | | | | | | | 2 | |
| | | | | | | | | 1x 4/1, 1x 4/12, 3x 4/179 | | | | | | |
| Vzorek B | | 406 | 66 | 16 | 10 | | | | | | | 7 | 7 | 100 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 456 | 19 | 4,1 | 5 | 0 | CVPG | 452 | 11 | 20% | 361 | 543 | 5 | |
| Ostatní | | | | | 5 | 0 | | | | | | | 2 | |
| | | | | | | | | 1x 4/1, 1x 4/12, 3x 4/179 | | | | | | |
| (193) Feritin | [µg/L] | | | | 16 | | | | | | | 15 | 14 | 93 |
| Vzorek A | | 267 | 73 | 27 | 16 | | | | | | | 15 | 14 | 93 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 296 | 27 | 9,2 | 5 | 0 | CVPG | 315 | 3,5 | 24% | 239 | 391 | 5 | |
| Ostatní | | | | | 11 | 0 | | | | | | | 10 | |
| | | | | | | | | 1x 4/1, 3x 4/12, 1x 4/162, 1x 4/179, 2x 6/58, 2x 6/60, 1x 6/178 | | | | | | |
| Vzorek B | | 157 | 37 | 23 | 16 | | | | | | | 15 | 14 | 93 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 173 | 39 | 23 | 5 | 0 | CVPG | 187 | 2,7 | 24% | 142 | 232 | 5 | |
| Ostatní | | | | | 11 | 0 | | | | | | | 10 | |
| | | | | | | | | 1x 4/1, 3x 4/12, 1x 4/162, 1x 4/179, 2x 6/58, 2x 6/60, 1x 6/178 | | | | | | |
| (321) FSH | [U/L] | | | | 10 | | | | | | | 10 | 10 | 100 |
| Vzorek A | | 39,8 | 3,8 | 9,5 | 10 | | | | | | | 10 | 10 | 100 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 38,5 | 1,4 | 3,8 | 5 | 0 | CVPG | 38 | 0,21 | 15% | 32,3 | 43,7 | 5 | |
| Ostatní | | | | | 5 | 0 | | | | | | | 5 | |
| | | | | | | | | 1x 4/1, 4x 4/12 | | | | | | |
| Vzorek B | | 5,27 | 0,48 | 9,2 | 10 | | | | | | | 10 | 10 | 100 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 5,13 | 0,12 | 2,3 | 5 | 0 | CVPG | 5,08 | 0,029 | 15% | 4,31 | 5,85 | 5 | |
| Ostatní | | | | | 5 | 0 | | | | | | | 5 | |
| | | | | | | | | 1x 4/1, 4x 4/12 | | | | | | |
| (328) hGH | [mU/L] | | | | 5 | | | | | | | 5 | 5 | 100 |
| Vzorek A | | | | | 5 | | | | | | | 5 | 5 | 100 |
| Ostatní | | | | | 5 | 0 | | | | | | 5 | | |
| | | | | | | | | 2x 4/12, 3x 4/29 | | | | | | |
| Vzorek B | | | | | 5 | | | | | | | 5 | 5 | 100 |
| Ostatní | | | | | 5 | 0 | | | | | | 5 | | |
| | | | | | | | | 2x 4/12, 3x 4/29 | | | | | | |
| (329) IGF-1 | [µg/L] | | | | 6 | | | | | | | 6 | 6 | 100 |
| Vzorek A | | | | | 6 | | | | | | | 6 | 6 | 100 |
| Ostatní | | | | | 6 | 0 | | | | | | 6 | | |
| | | | | | | | | 4x 4/29, 2x 4/60 | | | | | | |
| Vzorek B | | | | | 6 | | | | | | | 6 | 6 | 100 |
| Ostatní | | | | | 6 | 0 | | | | | | 6 | | |
| | | | | | | | | 4x 4/29, 2x 4/60 | | | | | | |
| (392) IGF-BP3 | [µg/L] | | | | 2 | | | | | | | 2 | 2 | 100 |
| Vzorek A | | | | | 2 | | | | | | | 2 | 2 | 100 |
| Ostatní | | | | | 2 | 0 | | | | | | 2 | | |
| | | | | | | | | 1x 4/29, 1x 4/60 | | | | | | |
| Vzorek B | | | | | 2 | | | | | | | 2 | 2 | 100 |
| Ostatní | | | | | 2 | 0 | | | | | | 2 | | |
| | | | | | | | | 1x 4/29, 1x 4/60 | | | | | | |
| (325) Inzulin | [mU/L] | | | | 7 | | | | | | | 7 | 7 | 100 |
| Vzorek A | | | | | 7 | | | | | | | 7 | 7 | 100 |
| Ostatní | | | | | 7 | 0 | | | | | | 7 | | |
| | | | | | | | | 1x 4/1, 1x 4/12, 3x 4/60, 2x 4/179 | | | | | | |
| Vzorek B | | | | | 7 | | | | | | | 7 | 7 | 100 |
| Ostatní | | | | | 7 | 0 | | | | | | 7 | | |
| | | | | | | | | 1x 4/1, 1x 4/12, 3x 4/60, 2x 4/179 | | | | | | |
| (326) Kyselina listová | [nmol/L] | | | | 15 | | | | | | | 15 | 14 | 93 |
| Vzorek A | | 46,3 | 5,8 | 12 | 15 | | | | | | | 15 | 15 | 100 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 42,9 | 3,7 | 8,6 | 8 | 0 | CVPG | 42 | 0,42 | 27% | 30,6 | 53,4 | 8 | |
| Ostatní | | | | | 7 | 0 | | | | | | | 7 | |
| | | | | | | | | 1x 4/1, 3x 4/12, 3x 4/179 | | | | | | |
| Vzorek B | | 6,55 | 1,8 | 28 | 15 | | | | | | | 15 | 14 | 93 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 5,21 | 1,3 | 26 | 8 | 0 | CVPG | 5,26 | 0,12 | 27% | 3,83 | 6,69 | 8 | |
| Ostatní | | | | | 7 | 0 | | | | | | | 7 | |
| | | | | | | | | 1x 4/1, 3x 4/12, 3x 4/179 | | | | | | |

Cyklus EHK: E21/24 - Endokrinologie 2

Stop termín: 2.2.2024

Nastavení: skupiny - M (princip měření), R (výrobce reagensů); Slovensko; minimální četnost skupin n = 5

| Zkouška Vzorek Skupina | [jednotka] | RoM | SD | CV [%] | N _{tot} | N _{out} | Srovnatelnost | | | | | N _{eva} | N _{suc} | S _{rel} [%] |
|---|------------|------|-------|-----------|------------------|------------------|------------------------------------|-----------------|------------------|-----|------|------------------|------------------|-------------------------|
| | | | | | | | AV | U _{AV} | D _{max} | LL | UL | | | |
| (320) LH | [U/L] | | | | 10 | | | | | | | 10 | 10 | 100 |
| Vzorek A | | 63,5 | 11 | 17 | 10 | | | | | | | 10 | 10 | 100 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 73,1 | 1,6 | 2,2 | 5 | 0 | CVPG | 75,6 | 0,5 | 15% | 64,2 | 87 | 5 | |
| Ostatní | | | | | 5 | 0 | | | | | | 5 | | |
| | | | | | | | 1x 4/1, 4x 4/12 | | | | | | | |
| Vzorek B | | 3,63 | 0,96 | 26 | 10 | | | | | | | 10 | 10 | 100 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 4,4 | 0,074 | 1,7 | 5 | 0 | CVPG | 4,63 | 0,038 | 15% | 3,93 | 5,33 | 5 | |
| Ostatní | | | | | 5 | 0 | | | | | | 5 | | |
| | | | | | | | 1x 4/1, 4x 4/12 | | | | | | | |
| (405) Parathyrin intaktní (PTH) | [pmol/L] | | | | 13 | | | | | | | 13 | 12 | 92 |
| Vzorek A | | 1,94 | 0,21 | 11 | 13 | | | | | | | 13 | 12 | 92 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 1,86 | 0,13 | 6,8 | 9 | 0 | CVPG | 1,79 | 0,017 | 23% | 1,37 | 2,21 | 9 | |
| Ostatní | | | | | 4 | 0 | | | | | | 4 | | |
| | | | | | | | 1x 4/1, 3x 4/12 | | | | | | | |
| Vzorek B | | 9,38 | 1,2 | 12 | 13 | | | | | | | 13 | 12 | 92 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 8,92 | 0,36 | 4 | 9 | 0 | CVPG | 8,54 | 0,075 | 23% | 6,57 | 10,6 | 9 | |
| Ostatní | | | | | 4 | 1 | | | | | | 4 | | |
| | | | | | | | 1x 4/1, 3x 4/12 | | | | | | | |
| (322) Prolaktin | [mU/L] | | | | 10 | | | | | | | 10 | 8 | 80 |
| Vzorek A | | | | | 10 | | | | | | | 10 | 9 | 90 |
| Ostatní | | | | | 10 | 0 | | | | | | 10 | | |
| | | | | | | | 1x 4/1, 3x 4/12, 4x 4/60, 2x 4/179 | | | | | | | |
| Vzorek B | | | | | 10 | | | | | | | 10 | 8 | 80 |
| Ostatní | | | | | 10 | 0 | | | | | | 10 | | |
| | | | | | | | 1x 4/1, 3x 4/12, 4x 4/60, 2x 4/179 | | | | | | | |
| (390) Renin | [ng/L] | | | | 3 | | | | | | | 2 | 1 | 50 |
| Vzorek A | | | | | 3 | | | | | | | 2 | 2 | 100 |
| Ostatní | | | | | 3 | 0 | | | | | | 2 | | |
| | | | | | | | 1x 1/185, 2x 4/164 | | | | | | | |
| Vzorek B | | | | | 3 | | | | | | | 2 | 1 | 50 |
| Ostatní | | | | | 3 | 0 | | | | | | 2 | | |
| | | | | | | | 1x 1/185, 2x 4/164 | | | | | | | |
| (394) SHBG | [nmol/L] | | | | 8 | | | | | | | 8 | 8 | 100 |
| Vzorek A | | 49,6 | 4,7 | 9,6 | 8 | | | | | | | 8 | 8 | 100 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 50,9 | 2,2 | 4,3 | 5 | 0 | CVPG | 49,2 | 0,37 | 20% | 39,3 | 59,1 | 5 | |
| Ostatní | | | | | 3 | 0 | | | | | | 3 | | |
| | | | | | | | 1x 4/1, 1x 4/12, 1x 4/179 | | | | | | | |
| Vzorek B | | 32,2 | 1,6 | 5,1 | 8 | | | | | | | 8 | 8 | 100 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 32,2 | 0,22 | 0,69 | 5 | 0 | CVPG | 31,6 | 0,24 | 20% | 25,2 | 38 | 5 | |
| Ostatní | | | | | 3 | 0 | | | | | | 3 | | |
| | | | | | | | 1x 4/1, 1x 4/12, 1x 4/179 | | | | | | | |
| (327) Vitamin B ₁₂ | [pmol/L] | | | | 15 | | | | | | | 15 | 15 | 100 |
| Vzorek A | | 543 | 88 | 16 | 15 | | | | | | | 15 | 15 | 100 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 597 | 78 | 13 | 8 | 0 | CVPG | 571 | 4,2 | 20% | 456 | 686 | 8 | |
| Ostatní | | | | | 7 | 0 | | | | | | 7 | | |
| | | | | | | | 1x 4/1, 3x 4/12, 3x 4/179 | | | | | | | |
| Vzorek B | | 418 | 76 | 18 | 15 | | | | | | | 15 | 15 | 100 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 466 | 42 | 9,1 | 8 | 0 | CVPG | 437 | 3,6 | 20% | 349 | 525 | 8 | |
| Ostatní | | | | | 7 | 0 | | | | | | 7 | | |
| | | | | | | | 1x 4/1, 3x 4/12, 3x 4/179 | | | | | | | |
| (319) Vitamin B ₁₂ (aktivní) | [pmol/L] | | | | 5 | | | | | | | 0 | | |
| Vzorek A | | | | | 5 | | | | | | | 0 | | |
| Ostatní | | | | | 5 | 0 | | | | | | 0 | | |
| | | | | | | | 1x 4/1, 4x 4/60 | | | | | | | |
| Vzorek B | | | | | 5 | | | | | | | 0 | | |
| Ostatní | | | | | 5 | 0 | | | | | | 0 | | |
| | | | | | | | 1x 4/1, 4x 4/60 | | | | | | | |